Artiva Biotherapeutics (ARTV) Free Cash Flow (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Free Cash Flow data on file, last reported at -$21.2 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 2.26% year-over-year to -$21.2 million in Q1 2026; TTM through Mar 2026 was -$77.5 million, a 27.58% decrease from a year earlier, with the FY2025 full-year figure at -$77.0 million, down 39.76% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$21.2 million, down from -$14.5 million in the prior quarter.
• Over the last five years, Free Cash Flow for ARTV reached as high as -$7.9 million in Q4 2023 and fell as low as -$22.4 million in Q2 2025.
• Historically, Free Cash Flow has averaged -$15.9 million across 4 years, with a median of -$14.8 million in 2024.
• On a YoY basis, Free Cash Flow climbed as much as 17.85% in 2024 and fell as far as 87.02% in 2024.
• Year by year, Free Cash Flow stood at -$7.9 million in 2023, then slumped by 87.02% to -$14.8 million in 2024, then gained by 1.76% to -$14.5 million in 2025, then tumbled by 45.75% to -$21.2 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$21.2 million in Q1 2026, -$14.5 million in Q4 2025, and -$19.3 million in Q3 2025.